Multifocal motor neuropathy (MMN) is a rare acquired immune-mediatedneuropathy characterized clinically by a purely motor deficit with conduction block and asymmetric multifocal weakness, fasciculatio...
Comprehensive, easy-to-understand information about this condition
How we create this content →Patient Advocacy Groups (PAGs) provide support, resources, and community for patients and caregivers.
Consider asking your healthcare providers these condition-specific questions
European rare disease database
Genetic and Rare Diseases Info Center
Patient Advocacy Groups (PAGs) provide support, resources, and community for patients and caregivers.
Consider asking your healthcare providers these condition-specific questions
European rare disease database
Genetic and Rare Diseases Info Center
The limited documentation surrounding multifocal motor neuropathy is reflective of its rarity, as conditions affecting fewer than 10 in 100,000 people often lack extensive clinical studies. The absence of identified genetic factors and the variability in clinical presentation further complicate the accumulation of comprehensive data. This makes it challenging for researchers and clinicians to fully characterize the condition, but ongoing research may provide more insights in the future.
To navigate your journey with multifocal motor neuropathy, consider consulting a neurologist with expertise in peripheral neuropathies, particularly those specializing in immune-mediated conditions. Resources such as the GBS/CIDP Foundation International and the Guillain-Barre & Associated Inflammatory Neuropathies organization can provide valuable support and information. Additionally, you may want to explore participation in clinical trials or patient registries to contribute to ongoing research and gain access to potential new treatments.
Currently, there is one FDA-approved treatment for MMN: immune globulin infusion (human). Additionally, empasiprubart has been designated as an orphan drug and is in development. There are also 7 active clinical trials exploring various aspects of MMN. You can find more information about these trials at ClinicalTrials.gov by searching for multifocal motor neuropathy. This ongoing research offers hope for improved understanding and management of the condition.
Actionable guidance for navigating care for multifocal motor neuropathy
To navigate your journey with multifocal motor neuropathy, consider consulting a neurologist with expertise in peripheral neuropathies, particularly those specializing in immune-mediated conditions. Resources such as the GBS/CIDP Foundation International and the Guillain-Barre & Associated Inflammatory Neuropathies organization can provide valuable support and information. Additionally, you may want to explore participation in clinical trials or patient registries to contribute to ongoing research and gain access to potential new treatments.
Consider asking your healthcare providers these condition-specific questions
Connect with organizations supporting the multifocal motor neuropathy community
Helpful links for rare disease information and support
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Feb 8, 2026
Patient Advocacy Groups (PAGs) provide support, resources, and community for patients and caregivers.
Consider asking your healthcare providers these condition-specific questions
European rare disease database
Genetic and Rare Diseases Info Center
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Organizations with approved therapies for this disease
No approved therapies yet
Research is ongoing — 2 companies have orphan drug designations for this disease
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.